We recently published a list of Why These 15 Healthcare Stocks Are Surging in 2025. In this article, we are going to take a look at where GRAIL, Inc. (NASDAQ:GRAL) stands against other healthcare stocks that are surging in 2025.

After lagging behind the broader market in 2024, many healthcare stocks are making a comeback this year. Healthcare spending has been continuously soaring and is projected to do so in the coming years due to demographic tailwinds. The industry now accounts for a fifth of the U.S. economy, and it’s a good idea to have exposure to it.

Most executives now hold a favorable view of the industry’s prospects, a notable increase from 52% just a year ago. Moreover, it’s an industry that is more insulated from tariffs and macro risks.

Of course, the top gainers here are not defensive healthcare stocks, but it’s still worth looking into the winners here if you are chasing potential multibaggers.

Even during bear markets, there are pockets of the market that perform exceptionally well. For example, I identified 15 Energy Stocks that are Up the Most in 2025 in another article.

Methodology

For this article, I screened the best-performing healthcare stocks year-to-date.

I will also mention the number of hedge fund investors in these stocks. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).

A scientist holding a vial of the cancer-fighting drug developed by the biotechnology company.

GRAIL, Inc. (NASDAQ:GRAL)

Number of Hedge Fund Holders In Q4 2024: 28

GRAIL, Inc. (NASDAQ:GRAL) is a biotechnology company focused on early cancer detection through its Galleri multi-cancer early detection blood test, which uses next-generation sequencing and machine learning to identify cancer signals from a simple blood draw.

The stock has soared in 2025, with the most significant boost coming after the announcement that TRICARE, one of the largest US health plans, would cover the Galleri test for adults over 50 at elevated cancer risk.

This coverage decision dramatically expanded the test’s addressable market and validated GRAIL, Inc. (NASDAQ:GRAL)’s commercial strategy, leading to a sharp increase in investor interest. GRAIL, Inc. (NASDAQ:GRAL) also reported strong financial results, with 2024 revenue up 35% year-over-year to $125.6 million and Galleri test revenue up 45% to $108.6 million.

In February 2025, GRAIL, Inc. (NASDAQ:GRAL) announced a partnership with Quest Diagnostics to integrate Galleri into Quest’s national test ordering system, further expanding access and distribution. The company completed major registrational studies in July 2024 and plans to submit for FDA approval in 2026.

The consensus price target of $26 implies 30.1% downside.

GRAL stock is up 108.40% year-to-date.

Overall, GRAL ranks 10th on our list of healthcare stocks that are surging in 2025. While we acknowledge the potential of GRAL as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than GRAL but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

 

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

 

Disclosure: None. This article is originally published at Insider Monkey.